Extreme Networks, Inc. (NASDAQ: EXTR) has entered into an asset purchase agreement for Avaya Networking, Inc. totaling $100 million, subject to adjustments. In January 2017, Avaya and certain of its subsidiaries filed for Chapter 11 bankruptcy in the Southern District of New York. Extreme Networks’ offer is subject to court approval. The company defined its offer in an 8K SEC filing on March 7, 2017 (http://dtn.fm/t3joR).
Extreme Networks, Inc. is a networking company based in San Francisco. It designs, builds and installs ethernet computer network products. It is a software-driven company that enables IT departments of clients to build stronger relationships with customers, employees, and partners. The company maintains more than 20,000 customers in some 80 countries. A key asset for Avaya is its award-winning fabric switching technology. Switching fabric typically includes data buffers.
Extreme Networks’ asset purchase agreement comes as a result of potential synergies with Avaya Networking, Inc., as identified by the EXTR management team. Extreme Networks believes it offers complementary products between the two businesses across the company’s vertical markets. For Extreme Networks’ clients, the deal, if court approved, would offer technology for edge switching environments in addition to secure access to Avaya’s data center. For Avaya, selling its networking business is seen by its management as a positive move, enabling it to focus on its unified communications core.
Extreme Networks believes that, if the offer is consummated, it could result in $200 million of added revenues annually. The acquisition is expected to be accretive to its own earnings and cash flow beginning in fiscal 2018. Extreme Networks intends to update its quarterly guidance and revenue if the acquisition is approved.
The tentative agreement remains subject to better offers, as Avaya plans to make a motion to the court to initiate a bidding and public auction process. On execution of the purchase agreement, Extreme Networks placed $10 million in escrow. Pending approval, these funds will be applied to the purchase of Avaya’s assets, but not to any of the firm’s liabilities. If the deal is not approved, Extreme Networks may be entitled to court-approved termination fees.
For more information, visit www.ExtremeNetworks.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Wednesday, March 15, 2017
eXp World Holdings, Inc. (EXPI) Rewards Its Real Revenue Drivers
To make more money from the same amount of work would seem to be only a dream. However, realtors at eXp Realty get paid a higher percentage rate than typical realtor splits and actually earn an equity piece of the company while building their businesses.
eXp World Holdings, Inc. (OTCQB: EXPI) is the publicly-traded holding company of eXp Realty, the agent owned cloud-based residential brokerage. The company’s increased payouts and perks helped eXp Realty nearly triple its agent count last year, with over 1,500 new real estate professionals joining in 2016. The company’s Q3 to Q3 trailing revenues were up 112 percent, coming in at $42.6 million.
The dramatic increase in agents and revenues reflects the environment built by the company’s unique business model. eXp Realty believes that the greatest asset of any real estate brokerage is the team of agents and brokers who create the revenues of the company.
Traditional agent-brokerage splits can range from 40 to 70 percent, depending on location and experience. Because of much lower operating costs, eXp Realty agents get paid 80 percent. Agents also get to own a part of the brokerage. They receive 100 shares with their first transaction and 500 shares once they generate about $80,000 in gross commission income. After exceeding that number and paying the brokerage its share, agents then go to a transaction-fee model for the remainder of the year, where they are paid 100 percent of their commission for each transaction minus $250 for the brokerage. To encourage recruitment, agents are further incentivized with 500 shares for each new agent recruited to the firm.
Real estate brokers and agents are sales driven people, and they’re the ones that drive revenues for the brokerage. Agents, like most everyone else, respond to incentives that benefit them and their families. Because it is cloud-based and more cost effective, eXp Realty can offer a commission structure that more greatly benefits its agents and ultimately drives more revenues for the company. Using shares as bonuses and incentives creates coherence between the agents and the company while at the same time enhancing agent retention. The bottom line is that eXp Realty knows how to incentivize and reward its agents, the real revenue drivers in any brokerage.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
eXp World Holdings, Inc. (OTCQB: EXPI) is the publicly-traded holding company of eXp Realty, the agent owned cloud-based residential brokerage. The company’s increased payouts and perks helped eXp Realty nearly triple its agent count last year, with over 1,500 new real estate professionals joining in 2016. The company’s Q3 to Q3 trailing revenues were up 112 percent, coming in at $42.6 million.
The dramatic increase in agents and revenues reflects the environment built by the company’s unique business model. eXp Realty believes that the greatest asset of any real estate brokerage is the team of agents and brokers who create the revenues of the company.
Traditional agent-brokerage splits can range from 40 to 70 percent, depending on location and experience. Because of much lower operating costs, eXp Realty agents get paid 80 percent. Agents also get to own a part of the brokerage. They receive 100 shares with their first transaction and 500 shares once they generate about $80,000 in gross commission income. After exceeding that number and paying the brokerage its share, agents then go to a transaction-fee model for the remainder of the year, where they are paid 100 percent of their commission for each transaction minus $250 for the brokerage. To encourage recruitment, agents are further incentivized with 500 shares for each new agent recruited to the firm.
Real estate brokers and agents are sales driven people, and they’re the ones that drive revenues for the brokerage. Agents, like most everyone else, respond to incentives that benefit them and their families. Because it is cloud-based and more cost effective, eXp Realty can offer a commission structure that more greatly benefits its agents and ultimately drives more revenues for the company. Using shares as bonuses and incentives creates coherence between the agents and the company while at the same time enhancing agent retention. The bottom line is that eXp Realty knows how to incentivize and reward its agents, the real revenue drivers in any brokerage.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
BioVie, Inc. (BIVI) Develops New Approaches to Devastating Liver Diseases
It’s estimated that over one million Americans and millions more worldwide suffer from liver cirrhosis. Globally, it accounted for over 1.2 million deaths in 2013, and it’s the 12th leading cause of death by disease in the United States, where 27,000 Americans die each year from the disease. Worldwide, 57 percent of cirrhosis is attributable to either hepatitis C or hepatitis B. Long-term alcohol abuse accounts for about 20 percent of cirrhosis-related deaths globally, while, in the United States, 40 percent of cirrhosis-related deaths are caused by alcohol abuse. Each of these disease drivers triggers the replacement of normal liver tissue with damaged scar tissue, which impedes blood flow and the liver’s ability to clean and purify blood.
Liver cirrhosis has multiple potential causes and often more than one of them can be found in the same patient. The disease’s most common complication is ascites, which is the abnormal accumulation of fluid in the abdomen, often accompanied by kidney dysfunction. This life-threatening condition causes severe suffering, frequent infections, and multiple complications that can lead to a painful death.
Currently, no approved medications to treat ascites are available. Diet change and drugs used off-label can provide some initial symptomatic relief, but, as the disease worsens, response rates fall. About 40 percent of patients die painfully within two years of diagnosis. The treatment costs for liver cirrhosis, including ascites and other complications, are deemed to be in excess of $4 billion annually in the U.S. alone.
The unquestioned human and financial toll of liver cirrhosis on patients, families, and society has created a real need for treatment solutions. One development stage biotechnology company, BioVie, Inc. (OTCQB: BIVI), is pioneering just such innovative treatment solutions. BioVie actively pursues the discovery, development, and commercialization of innovative drug therapies for liver diseases. Just four months ago, BioVie submitted an Investigational New Drug (IND) application for its initial drug candidate, BIV201, to the U.S. Food and Drug Administration (FDA). This new drug has the potential to become the first drug approved by the FDA to treat ascites due to chronic liver cirrhosis and could become the breakthrough treatment so desperately needed around the world.
For more information, visit www.BioVieInc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Liver cirrhosis has multiple potential causes and often more than one of them can be found in the same patient. The disease’s most common complication is ascites, which is the abnormal accumulation of fluid in the abdomen, often accompanied by kidney dysfunction. This life-threatening condition causes severe suffering, frequent infections, and multiple complications that can lead to a painful death.
Currently, no approved medications to treat ascites are available. Diet change and drugs used off-label can provide some initial symptomatic relief, but, as the disease worsens, response rates fall. About 40 percent of patients die painfully within two years of diagnosis. The treatment costs for liver cirrhosis, including ascites and other complications, are deemed to be in excess of $4 billion annually in the U.S. alone.
The unquestioned human and financial toll of liver cirrhosis on patients, families, and society has created a real need for treatment solutions. One development stage biotechnology company, BioVie, Inc. (OTCQB: BIVI), is pioneering just such innovative treatment solutions. BioVie actively pursues the discovery, development, and commercialization of innovative drug therapies for liver diseases. Just four months ago, BioVie submitted an Investigational New Drug (IND) application for its initial drug candidate, BIV201, to the U.S. Food and Drug Administration (FDA). This new drug has the potential to become the first drug approved by the FDA to treat ascites due to chronic liver cirrhosis and could become the breakthrough treatment so desperately needed around the world.
For more information, visit www.BioVieInc.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
GreeneStone Healthcare Corp. (GRST) Helping Tackle the Effects of Substance Abuse on Young Adults and Children in Florida
Addiction, a chronic brain disease that induces compulsive activity leading to many legal, social, and health consequences, is a problem that has swept over the world. Although this disease may start as a positive experience for the user, the outcome is normally devastating or even fatal. In the U.S., pharmaceutical opioids and heroin are two of the most problematic substances, causing thousands of deaths annually.
However, it’s not just opioids and heroin causing problems. Millions of Americans are addicted to other drugs and alcohol. Florida, specifically, is known as a state of hard drinking. It is also known as a party destination for spring breakers. Approximately 58% of Floridians are drinkers, with around 15% of these being heavy drinkers (http://dtn.fm/EC47x).
The combination of Florida being a well-known center for drug trafficking and a go-to spring break destination has led to youth and young adult substance abuse in the state becoming a critical problem. According to DrugRehab.com (http://dtn.fm/hG32R), “In 2015, of those in Florida who sought rehab, 47.5 percent of people addicted to heroin and 48.2 percent of people addicted to opioids were aged 30 and under.” In addition, of all the patients admitted to rehabilitation facilities in Florida in 2015, more than 3,000 of these were children aged below 18 years old. This equates to 10.6% of the total number of admitted patients.
It is not only the children and young adults with substance abuse and addiction who are suffering the consequences of the drugs. Parents with chemical dependencies often have tragic effects on their own children. Aside from potentially leaving children with the same substance addiction, these parents often neglect their offspring. DrugRehab.com reports that such emotional and physical neglect, and sometimes related abuse, caused more than 230 child deaths in Florida between 2008 and 2014. Fortunately, more is being done by organizations to overcome this statewide problem.
Treatment is essential for both adults and children hooked on opiates, heroin, and other substances. The best way to overcome this problem is residential treatment, something Greenestone Healthcare Corp. (OTCQB: GRST) can now offer Floridians, following its recent acquisition of Seastone Drug Rehab in Delray Beach, Florida.
The company, which offers addiction and rehabilitation treatment services, some of which include counseling, coaching, intervention, psychological assessment, and more, uses a unique approach to substance abuse recovery, focusing on treating any underlying disorders that could have encouraged the addiction.
By working with medical professionals at the clinic, as well as the patient’s family and friends, Seastone is uniquely equipped to help adults in Florida and around the country overcome their addiction. This will hopefully result in fewer children suffering both the mental and physical consequences of their parents or guardians addiction, leading to fewer child deaths as a result of neglect and/or abuse.
For more information, visit the company’s website at www.GreeneStone.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
However, it’s not just opioids and heroin causing problems. Millions of Americans are addicted to other drugs and alcohol. Florida, specifically, is known as a state of hard drinking. It is also known as a party destination for spring breakers. Approximately 58% of Floridians are drinkers, with around 15% of these being heavy drinkers (http://dtn.fm/EC47x).
The combination of Florida being a well-known center for drug trafficking and a go-to spring break destination has led to youth and young adult substance abuse in the state becoming a critical problem. According to DrugRehab.com (http://dtn.fm/hG32R), “In 2015, of those in Florida who sought rehab, 47.5 percent of people addicted to heroin and 48.2 percent of people addicted to opioids were aged 30 and under.” In addition, of all the patients admitted to rehabilitation facilities in Florida in 2015, more than 3,000 of these were children aged below 18 years old. This equates to 10.6% of the total number of admitted patients.
It is not only the children and young adults with substance abuse and addiction who are suffering the consequences of the drugs. Parents with chemical dependencies often have tragic effects on their own children. Aside from potentially leaving children with the same substance addiction, these parents often neglect their offspring. DrugRehab.com reports that such emotional and physical neglect, and sometimes related abuse, caused more than 230 child deaths in Florida between 2008 and 2014. Fortunately, more is being done by organizations to overcome this statewide problem.
Treatment is essential for both adults and children hooked on opiates, heroin, and other substances. The best way to overcome this problem is residential treatment, something Greenestone Healthcare Corp. (OTCQB: GRST) can now offer Floridians, following its recent acquisition of Seastone Drug Rehab in Delray Beach, Florida.
The company, which offers addiction and rehabilitation treatment services, some of which include counseling, coaching, intervention, psychological assessment, and more, uses a unique approach to substance abuse recovery, focusing on treating any underlying disorders that could have encouraged the addiction.
By working with medical professionals at the clinic, as well as the patient’s family and friends, Seastone is uniquely equipped to help adults in Florida and around the country overcome their addiction. This will hopefully result in fewer children suffering both the mental and physical consequences of their parents or guardians addiction, leading to fewer child deaths as a result of neglect and/or abuse.
For more information, visit the company’s website at www.GreeneStone.net
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Tuesday, March 14, 2017
India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”
India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions.
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson’s, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC’s strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. “The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers’ Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York’s Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.
For more information, visit the company’s website at www.IGCinc.us
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its focus on combination therapy it can formulate and commercialize cannabinoid compounds as an alternative to long-term addictive opioid treatments.
The Company has also filed combination therapy formulations for the treatment of epilepsy and cachexia. About 50 million people worldwide are affected by epilepsy and about 1.3 million in the U.S. experience cachexia associated with cancer, MS, Parkinson’s, HIV/AIDS and other progressive illnesses. Cancer-induced anorexia/cachexia is responsible for 20% of all cancer deaths. IGC-502 indicated for seizures and IGC-504 indicated for cachexia are unique combination therapies that, if proven out by clinical trials, are expected to treat medical refractory epilepsy and eating disorders respectively, with lower side effects than conventional mono therapies.
IGC’s strategy is exciting and unique in that it is aiming to become a leader in the phytocannabinoid-based combination therapy specialty pharmaceutical sector. This first mover advantage can potentially be formidable as it begins clinical trials and further builds its patent portfolio. “The development of combination therapies utilizing cannabis represents a large, unique opportunity in this emerging specialty-pharmaceutical sector. Securing FDA approval for combination therapy is believed to be significantly faster and less expensive than new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” stated Ram Mukunda, CEO.
IGC has recently exited its legacy businesses and currently holds international investments in land and in a hotel project. An impressive and experienced team, led by Mr. Ram Mukunda, CEO, directs IGC.
Mr. Mukunda holds degrees in Electrical Engineering and Mathematics from the University of Maryland (UMD). He founded and served as Chairman and CEO of Startec Global Communications, an international telecommunications carrier focused on providing voice over Internet protocol (VOIP) services to emerging economies. Startec, the first pure play international long distance carrier, went public on NASDAQ. He has won a number of awards, including the 2013 University of Maryland International Alumnus of the year award. Mr. Mukunda serves as an Emeritus member on the Board of Visitors at the University of Maryland, School of Engineering, and has served as Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. Mr. Mukunda and Dr. Krishna are the originators of all the IGC patent filings.
Dr. Ranga Krishna, Senior Advisor, is a Board Certified Neurologist with a sub specialty in Epilepsy surgery. He is the Director of Neurology at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College and the Director of Stroke Service at the New York Community Hospital affiliated with New York Presbyterian Weil Cornell Medical College. He is the Medical Director and Chairman of Total Neuro Care, P.C. He is CEO of International Pharma Trials, Inc., which assists U.S. pharmaceutical companies perform Phase II clinical trials. Dr. Krishna is a member of several organizations, including the American Academy of Neurology and the Medical Society of the State of New York. He is also a member of the Medical Arbitration panel for the New York State Workers’ Compensation Board and a Founding Member of the New York State Pain Society. Dr. Krishna was trained at New York’s Mount Sinai Medical Center (1991-1994) and New York University (1994-1996). Dr. Krishna and Mr. Mukunda are the originators of all the IGC patent filings.
For more information, visit the company’s website at www.IGCinc.us
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
TapImmune, Inc. (NASDAQ: TPIV) is “One to Watch”
TapImmune, Inc. (NASDAQ: TPIV) is leading the field of oncology with its next-generation T-cell vaccines and novel immunotherapy platforms. By fully leveraging the scope of its technology and through collaborative partnerships and license agreements, the company aims to maximize its value and growth potential.
Most cancer patients die from metastatic disease, which is when the cancer travels to other parts of the body that ultimately cannot be treated, instead of the primary tumor. TapImmune’s immunotherapies overcome the deficiencies of earlier cancer vaccine approaches by targeting both tumors and metastatic diseases. The company’s approach further differentiates itself by influencing the body’s own immune system to fight the disease.
Two clinical stage T-cell vaccine candidates are currently being advanced in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from the FDA Fast Track and Orphan Disease Designation. The U.S. market alone is very large for these cancers, with a combined 290,000 new patients estimated to be diagnosed each year. Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca are among the collaborators in these trials, and the U.S. Department of Defense has provided significant non-dilutive funding as well.
The company’s off-the-shelf vaccines have been proven to boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to treat a wide patient population across varied therapeutic areas of cancer. These vaccines have the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics.
PolyStart is TapImmune’s unique DNA-based antigen expression system that helps the body recognize and kill target cells. It is a novel vaccine technology platform that creates a four-fold or greater increase in presentation of any antigen, which gives it unlimited application in oncology and infectious disease. The PolyStart platform further solidifies the company as a leader in the development of next-generation vaccines for cancer as it will be able to use this technology for its own vaccine candidates as well as generate additional value for the platform by licensing it to third parties.
The company plans to first build value through advancing candidates that treat women’s cancers, while continuously developing its unique pipeline. As part of its long-term vision, the company is also developing proprietary technologies that can enhance the potency of DNA-based immunotherapies against other types of cancer and infectious disease. Other goals include discovering, acquiring and developing additional technologies that modulate antigen presentation and driving incremental value by monetizing proprietary protein expression systems through business partnerships.
For more information, visit the company’s website at www.TapImmune.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Most cancer patients die from metastatic disease, which is when the cancer travels to other parts of the body that ultimately cannot be treated, instead of the primary tumor. TapImmune’s immunotherapies overcome the deficiencies of earlier cancer vaccine approaches by targeting both tumors and metastatic diseases. The company’s approach further differentiates itself by influencing the body’s own immune system to fight the disease.
Two clinical stage T-cell vaccine candidates are currently being advanced in multiple Phase II and Phase Ib/IIa clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from the FDA Fast Track and Orphan Disease Designation. The U.S. market alone is very large for these cancers, with a combined 290,000 new patients estimated to be diagnosed each year. Mayo Clinic, Memorial Sloan Kettering Cancer Center, and AstraZeneca are among the collaborators in these trials, and the U.S. Department of Defense has provided significant non-dilutive funding as well.
The company’s off-the-shelf vaccines have been proven to boost patients’ immune systems to comprehensively stimulate both killer T-cells and helper T-cells to destroy cancer cells, and they are designed to treat a wide patient population across varied therapeutic areas of cancer. These vaccines have the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics.
PolyStart is TapImmune’s unique DNA-based antigen expression system that helps the body recognize and kill target cells. It is a novel vaccine technology platform that creates a four-fold or greater increase in presentation of any antigen, which gives it unlimited application in oncology and infectious disease. The PolyStart platform further solidifies the company as a leader in the development of next-generation vaccines for cancer as it will be able to use this technology for its own vaccine candidates as well as generate additional value for the platform by licensing it to third parties.
The company plans to first build value through advancing candidates that treat women’s cancers, while continuously developing its unique pipeline. As part of its long-term vision, the company is also developing proprietary technologies that can enhance the potency of DNA-based immunotherapies against other types of cancer and infectious disease. Other goals include discovering, acquiring and developing additional technologies that modulate antigen presentation and driving incremental value by monetizing proprietary protein expression systems through business partnerships.
For more information, visit the company’s website at www.TapImmune.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Monday, March 13, 2017
eXp World Holdings, Inc. (EXPI) Capitalizing on the Benefits of Cloud-Based Learning Management Systems
Cloud-based Learning Management Systems (LMS) are “predicted to revolutionize both the way we learn as students and the way we learn on the job” according to Capterra (http://dtn.fm/Gz7Yi). The article continues to explain that more and more organizations are likely to adopt cloud-based LMS in the coming years.
Cloud-based Learning Management Systems are web-hosted platforms used by organizations to deliver, manage, and track online training programs for their employees. One of the industries highlighted as a user of LMS software is the real estate industry, and eXp World Holdings, Inc. (OTCQB: EXPI), holding company for a cloud-based, agent-owned real estate brokerage, is one company in the sector that’s taking advantage of the many benefits offers by cloud-based LMS.
In fact, the company’s eXp Realty subsidiary is a full-service real estate brokerage that offers 24/7 access to collaborative tools and socialization features to its agents and brokers through its 3-D, cloud office environment. In addition to collaborative tools and socialization, EXPI offers its agents a full network of online training resources.
As well as introducing lower setup costs, this method of training is easy to maintain and, according to eLearning Industry (http://dtn.fm/bUL0M), increases productivity and job satisfaction. The article explains that virtual training saves time and money, and it is far more appealing to employees, or, in this case, agents and brokers, as they can access courses from anywhere at any time.
The eXp World Holdings training platform is accessible to agents and brokers all day, every day, for free. The system EXPI uses provides flexible training options to agents whereby they can improve and advance their eXp Realty operations. The platform offers a range of courses to choose from with the opportunity to attend meetings and company presentations as well.
This user-friendly way of learning is completely secure, and it allows for more effective training, as users can learn in their chosen environments, from any device. Courses can be uploaded easily and improved upon with time. Aside from the high-quality training, EXPI agents and brokers are able to increase their listings and sales while reducing their overhead and capital requirements.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Cloud-based Learning Management Systems are web-hosted platforms used by organizations to deliver, manage, and track online training programs for their employees. One of the industries highlighted as a user of LMS software is the real estate industry, and eXp World Holdings, Inc. (OTCQB: EXPI), holding company for a cloud-based, agent-owned real estate brokerage, is one company in the sector that’s taking advantage of the many benefits offers by cloud-based LMS.
In fact, the company’s eXp Realty subsidiary is a full-service real estate brokerage that offers 24/7 access to collaborative tools and socialization features to its agents and brokers through its 3-D, cloud office environment. In addition to collaborative tools and socialization, EXPI offers its agents a full network of online training resources.
As well as introducing lower setup costs, this method of training is easy to maintain and, according to eLearning Industry (http://dtn.fm/bUL0M), increases productivity and job satisfaction. The article explains that virtual training saves time and money, and it is far more appealing to employees, or, in this case, agents and brokers, as they can access courses from anywhere at any time.
The eXp World Holdings training platform is accessible to agents and brokers all day, every day, for free. The system EXPI uses provides flexible training options to agents whereby they can improve and advance their eXp Realty operations. The platform offers a range of courses to choose from with the opportunity to attend meetings and company presentations as well.
This user-friendly way of learning is completely secure, and it allows for more effective training, as users can learn in their chosen environments, from any device. Courses can be uploaded easily and improved upon with time. Aside from the high-quality training, EXPI agents and brokers are able to increase their listings and sales while reducing their overhead and capital requirements.
For more information, visit the company’s website at www.eXpWorldHoldings.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
Subscribe to:
Posts (Atom)
